A dual precision therapy developed by Professor Maher Gandhi, is expected to revolutionise the care given to those diagnosed with a rare form of lymphoma in immunocompromised people.

During a world first therapy, Mater Researcher and Haematologist Professor Maher Gandhi 46-year-old patient Scott Griffiths has been successfully cured of a rare type of lymphoma.

Launched in early September, the taskforce has begun to help raise awareness for Australian living with blood cancers to get the help they need.

The Blood Cancer Taskforce, a collaboration of some of the country’s top blood cancer experts and leaders launched today.

Mater Research CEO Professor Maher Gandhi has been appointed to a new National Blood Cancer Taskforce to deliver Australia’s first National Strategic Action Plan for Blood Cancer.

Mater Research CEO and MRI-UQ Director Professor Maher Gandhi and his team report that immune-infiltration is a promising tool to improve outcomes for patients with follicular lymphoma.

More Australians living with follicular lymphoma could benefit from tailored treatment through development of a new clinical scoring model thanks to Mater Research.

Mater Research CEO Professor Maher Gandhi has secured additional funding from the Leukaemia Foundation to investigate a new therapeutic approach for follicular lymphoma (FL).

Professor Maher Gandhi will be appointed as Chief Executive Officer of Mater Research and Director of MRI-UQ, effective May 1 2019.

Mater Research—University of Queensland (MRI—UQ) Acting Director Professor Maher Gandhi has been awarded $3.6 million to improve treatment for relapsed lymphoma patients.

Following an international search, Professor Maher Gandhi has been appointed Director of Clinical Research at Mater Research.